Cathepsin K-Dependent Toll-Like Receptor 9 Signaling Revealed in Experimental Arthritis

Masataka Asagiri(Tokyo Medical and Dental University), Toshitake Hirai(Tokyo Medical and Dental University), Toshihiro Kunigami(Tokyo Medical and Dental University), Shunya Kamano(Tokyo Medical and Dental University), Hans-Jürgen Gober(Tokyo Medical and Dental University), Kazuo Okamoto(Tokyo Medical and Dental University), Keizo Nishikawa(Tokyo Medical and Dental University), Eicke Latz(Tokyo Medical and Dental University), Douglas T. Golenbock(Tokyo Medical and Dental University), Kazuhiro Aoki(Tokyo Medical and Dental University), Keiichi Ohya(Tokyo Medical and Dental University), Yuuki Imai(Tokyo Medical and Dental University), Yasuyuki Morishita(Tokyo Medical and Dental University), Kohei Miyazono(Tokyo Medical and Dental University), Shigeaki Kato(Tokyo Medical and Dental University), Paul Säftig(Tokyo Medical and Dental University), Hiroshi Takayanagi(Tokyo Medical and Dental University)
Science
February 1, 2008
Cited by 361

Abstract

Cathepsin K was originally identified as an osteoclast-specific lysosomal protease, the inhibitor of which has been considered might have therapeutic potential. We show that inhibition of cathepsin K could potently suppress autoimmune inflammation of the joints as well as osteoclastic bone resorption in autoimmune arthritis. Furthermore, cathepsin K-/- mice were resistant to experimental autoimmune encephalomyelitis. Pharmacological inhibition or targeted disruption of cathepsin K resulted in defective Toll-like receptor 9 signaling in dendritic cells in response to unmethylated CpG DNA, which in turn led to attenuated induction of T helper 17 cells, without affecting the antigen-presenting ability of dendritic cells. These results suggest that cathepsin K plays an important role in the immune system and may serve as a valid therapeutic target in autoimmune diseases.


Related Papers

No related papers found

Powered by citation graph analysis